VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rocketman who wrote (6607)	4/22/1999 7:16:00 PM
From: aknahow	Read Replies (1) of 9719

O.T. an informed opinion on the validity of the following statement would be appreciated. xoma.com "XOMA's Human Engineering (HE) technology presents a new paradigm for antibody humanization, a novel alternative to CDR-grafting methods. The XOMA method uses a unique residue-by-residue analysis to determine which amino acid residues along the non-human antibody variable region can be humanized and which need to remain non-human in order to preserve binding affinity and proper protein folding." If this statement is off the mark and not correct, I would like to know it. The use of the phrase, "new paradigm", is a bit out of corporate character for XOMA.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next